Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Nitty gritty Manual for Picking Agreeable Tennis shoes - 2The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- 3Moon rush: These private spacecraft will attempt lunar landings in 2026
- 4Becoming amazing at Systems administration: Individual and Expert Tips
- 5Qatar LNG Ships U-Turn After Attempt to Pass Through Hormuz
- NASA's Artemis 2 moon launch may be visible from Florida and southern Georgia today. Here's when to look
- How color-changing, bacteria-infused spacesuits could help keep future astronauts safe from space radiation
- Best Amusement Park in Europe: Where Do You Very much want to Visit?
- How to watch ‘The Traitors’ Season 4: Premiere date, episode release time, full cast list and more
- How comfort foods trigger pleasure in our brains
- How to get rid of your Christmas tree — and the 1 thing to never, ever do with it
- Vote In favor of Your Favored Comupter Game
- Enormous Credit And All that You Really want To Be aware
- CDC clarifies stance on vaccines and autism, stating no evidence supports the link
